Skip to main content
Lyrea avatar

Not yet reviewed — this article is pending editorial review by Lyrea.

Citation noticeOur citation system is being overhauled

References and citation markers may currently be incomplete, mismatched, or incorrect. This system is being rebuilt and reviewed before the full site launch.

GHB

GHB molecule structureGHB molecule structure
Psychoactive Class
Chemical Class

GHB is a depressant that occurs naturally in the human body. First synthesized in the 1920s, it has seen varied use as an anesthetic, a bodybuilding supplement, and eventually a recreational club drug by the late 1990s. It is known for producing euphoric, disinhibiting, and sedative effects. GHB carries notable risks due to inconsistent concentrations in commonly sold liquid form and dangerous interactions with other depressants.

Dosage & Duration

Dosage

Doses are population estimates that vary widely between individuals.

Threshold~0.5 g
Light0.5-1.5 g
Moderate1.5-2.5 g
Strong2.5-3.5 g
Heavy3.5+ g

Doses of 3 grams or more commonly produce heavy sedation, while amounts exceeding 3.5 grams carry a significant risk of sudden loss of consciousness. Because the margin between desired effects and dangerous overdose is narrow, precise measurement with calibrated equipment is critical. If onset is slower than expected, allow a minimum of two hours before considering any additional dose.

Duration

Onset20-60 minutes
After Effects2-4 hours
Total1.5-2.5 hours

Subjective Effects

Legacy content. A statistically backed ontology from Mindstate Design Labs is coming soon.

Effects vary widely by individual, dose, and context.

Physical

The physical effects of GHB can be broken down into several components which progressively intensify proportional to dosage.

EuphoriaNauseaMotor control lossDizzinessDehydration

Cognitive

The cognitive effects of GHB can be broken down into several components which progressively intensify proportional to dosage.

Forked from Subjective Effect Documentation byJosie Kins September 2015.

Pharmacology

Pharmacodynamics

GHB acts as an agonist at excitatory GHB receptors and as a weak agonist at inhibitory GABA-B receptors. The GHB receptor, which is densely expressed in cortical and hippocampal regions, represents the higher-affinity binding site. At elevated brain concentrations, GABA-B receptor activation becomes pharmacologically predominant and is primarily responsible for the substance's sedative properties. GHB also exerts a biphasic effect on dopamine release: at low concentrations it stimulates dopamine release via the GHB receptor, while at higher concentrations it inhibits dopamine release through GABA-B receptor activation, with dopamine release subsequently increasing again as GHB concentrations decline below the GABA-B activation threshold. Activation of the GHB receptor has additionally been associated with glutamate release in certain brain areas.

Pharmacokinetics

The vast majority of an administered GHB dose (95–98%) undergoes extensive hepatic metabolism, with only 1–5% excreted unchanged in urine. The primary metabolic pathway involves conversion to succinic semialdehyde (SSA) by GHB dehydrogenase or GHB transhydrogenase. SSA is subsequently oxidized by succinic semialdehyde dehydrogenase (SSADH) to succinic acid, which enters the Krebs cycle and is ultimately converted to carbon dioxide and water.

Interactions

Interactions not written up yet

An unlisted combination is an unknown one, not a safe one. Check a dedicated combination chart before mixing.

Check TripSit

Tolerance

Tolerance timelines are rules of thumb, not exact schedules, and vary widely between individuals and use patterns.

Full Tolerance
Regular use can lead to physical dependence, particularly with chronic high-dose consumption involving multiple daily doses. The development of tolerance appears to occur alongside dependence formation.
Cross Tolerance

Other GABAergic depressants

Harm Potential

Addiction & Dependence

Psychological

Moderate

GHB is classified as habit-forming with recognized addiction potential. Repeated use can disrupt brain circuits controlling rewards, memory and cognition, leading to compulsive drug-taking patterns.

Physical

High

Chronic high-dose consumption leads to severe physical dependence. Withdrawal symptoms include insomnia, anxiety, tremor, sweating, and muscle cramps, typically resolving within three to twenty-one days. The withdrawal syndrome can be severe, producing acute delirium that may require hospitalization in an intensive care unit. Medical supervision is strongly recommended for discontinuation.

Toxicity

Central Nervous System

Chronic administration in animal studies has been associated with impairments in spatial memory, working memory, and learning; relevance to human recreational use at typical doses is not fully established.

Psychosis Risk

Acute psychotic symptoms are not typically associated with GHB intoxication itself, but withdrawal can produce acute delirium requiring intensive care management. Benzodiazepines are the mainstay of treatment, often at higher doses than required for delirium from other causes.

Seizure Risk

Convulsions can occur at very high doses and are more likely when GHB is combined with stimulants. Severe physical withdrawal from chronic high-dose use can produce epileptic seizures. At very high doses, uncontrollable muscle twitching may occur which can progress to epileptic activity.

History & Culture

Early Research and Medical Development

The chemical family to which GHB belongs was first explored by Russian chemist Alexander Zaytsev, who published work on related compounds in 1874. The compound itself was first synthesized in the 1920s, though it would remain largely unexamined for several decades.

Legality

By Country

Illegal2
United States flagUnited StatesIllegal
United Kingdom flagUnited KingdomIllegal

References

Citations

  1. NIH PubChem GHB compound property record. pubchem.ncbi.nlm.nih.gov (n.d.). https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/name/gamma-hydroxybutyric%20acid/property/IUPACName,Title,CanonicalSMILES,IsomericSMILES,InChIKey,MolecularFormula/JSON1
  2. Home Office Circular 001/2022: Reclassification of GHB and related substances. gov.uk (n.d.). https://www.gov.uk/government/publications/circular-0012022-reclassification-of-ghb-and-related-substances/circular-0012022-reclassification-of-ghb-and-related-substances1
  3. Home Office list of most commonly encountered drugs currently controlled. gov.uk (n.d.). https://www.gov.uk/government/publications/controlled-drugs-list--2/list-of-most-commonly-encountered-drugs-currently-controlled-under-the-misuse-of-drugs-legislation1
  4. Misuse of Drugs Act 1971 (Modification) Order 2003 (S.I. 2003/1243). legislation.gov.uk (n.d.). https://www.legislation.gov.uk/uksi/2003/1243/made/data.xml1
  5. Home Office Circular 001/2015 on GHB rescheduling. gov.uk (n.d.). https://www.gov.uk/government/publications/circular-0012015-a-change-to-the-misuse-of-drugs-act-1971-control-of-ah-7921-lsd-related-compounds-tryptamines-and-rescheduling-of-ghb/circular-0012015-a-change-to-the-misuse-of-drugs-act-1971-control-of-ah-7921-lsd-related-compounds-tryptamines-and-rescheduling-of-ghb1
  6. Misuse of Drugs Act 1971, current revised Schedule 2. legislation.gov.uk (n.d.). https://www.legislation.gov.uk/ukpga/1971/38/schedule/21
  7. Misuse of Drugs Act 1971 (Amendment) Order 2022 (S.I. 2022/322). legislation.gov.uk (n.d.). https://www.legislation.gov.uk/uksi/2022/322/made/data.xml1
  8. Misuse of Drugs Regulations 2001, current revised Schedule 2. legislation.gov.uk (n.d.). https://www.legislation.gov.uk/uksi/2001/3998/schedule/21
  9. Misuse of Drugs Act 1971, section 2. legislation.gov.uk (n.d.). https://www.legislation.gov.uk/ukpga/1971/38/section/2?view=plain1
  10. Misuse of Drugs Act 1971, section 4. legislation.gov.uk (n.d.). https://www.legislation.gov.uk/ukpga/1971/38/section/4?view=plain1

Article Status

  • Josie Kins avatar
    Step 1 · Automated synthesis

    An autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.

  • Step 2 · First-pass reviewPending

    Not yet reviewed — this article is pending editorial review by Lyrea.

  • Step 3 · Citation reviewPending

    No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.

Recent changes8 human edits · latest

Times are UTCNewest first

28 August 2026

  1. Lyrea · Updated the article

  2. Lyrea · Updated the article

24 January 2026

  1. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  2. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  3. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  4. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  5. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

  6. Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more

All changes to this article · Site-wide recent changes

Suggest an edit

Spotted a mistake, an outdated claim, or something missing from the GHB article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.

Wish to give generalised feedback? You can do so here.